NEW YORK, Aug. 26, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver and intestinal diseases, today announced management will be participating in the following upcoming investor conferences:
- Dr. Mark Pruzanski, Chief Executive Officer, will participate in a panel session at Citi's 9th Annual Biotech Conference on Wednesday, September 3, 2014 in Boston
- Dr. Pruzanski will present at the Morgan Stanley Global Healthcare Conference at 4:05 p.m. ET on Tuesday, September 9, 2014 in New York
- Dr. Pruzanski will present at the Bank of America Merrill Lynch Global Healthcare Conference on Thursday, September 18, 2014 at 9:45 a.m. GMT in London
Information for the availability of live webcasts for these events will be posted on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks following each webcast event.
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver and intestinal diseases utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is being developed for a variety of chronic liver diseases including primary biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH), alcoholic hepatitis and primary sclerosing cholangitis (PSC). OCA has received orphan drug designation in both the United States and Europe for the treatment of PBC and PSC. Intercept owns worldwide rights to OCA outside of Japan, China and Korea, where it has out-licensed the product candidate to Sumitomo Dainippon Pharma. For more information about Intercept, please visit the Company's website at: www.interceptpharma.com
CONTACT: For more information about Intercept, please contact Barbara Duncan or Senthil Sundaram, both of Intercept Pharmaceuticals at 1-646-747-1000. Media inquiries: email@example.com Investor inquiries: firstname.lastname@example.org
Source:Intercept Pharmaceuticals, Inc.